PTX-200 High Overall Response in Ph2a Breast Cancer trial
Filed with ASX · · 6 pages · English
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- Encouraging data from PTX-200 ovarian cancer trial
- Third complete response in PTX-200 AML Trial
- PTX in new CAR-T collaboration
- 1st patient dosed in trial for first in class drug PTX-100
- Receipt of R&D Tax Rebate
Later from Prescient Therapeutics
- December 2019 Appendix 4C - Quarterly
- March 2020 Quarterly Update and Appendix 4C
- PTX-100 progresses to new dose, adds new site
- Pause in Trading
- Voluntary Suspension
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics